02:16:14 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-15 Årsstämma 2024
2024-04-25 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 Ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 Ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2022-10-17 14:31:28

Company Announcement

Copenhagen, Denmark, October 17, 2022 - Brain+ A/S (Nasdaq First North: BRAINP)

The information communicated in this announcement is "inside information" for the purposes of article 19 of the Market Abuse Regulation 596/2014

On October 17[th] 2022, Kim Baden-Kristensen, CEO & Co-founder of Brain+ A/S ("Brain+) and members of the board of Brain+, Lars Terney, Vice Chairman, and Hanne Leth Hillman, Chair of the Audit Committee (collectively "the Investors"), chose to exercise all of their warrants of series TO 1 (BRAINP TO, ISIN: DK0061670551), to subscribe for newly issued shares in Brain+ A/S.

  • In connection with Brain+'s IPO in October 2021, the company issued 4.8m publicly traded warrants, which can be exercised to subscribe for new shares in Brain+ A/S between October 17[th] and October 31[st] 2022, at an exercise price of DKK 1.638 per share.
  • The Investors have collectively subscribed to 311.238 newly issued Brain+ shares (BRAINP, ISIN: DK0061670205) via exercise of their entire warrant holdings, at the exercise price of DKK 1.638 per share, for a total consideration of DKK 509.808.
  • The collective market value of shares acquired to date by the Investors, including these newly subscribed shares, is DKK 8.5m based on the share price as of October 14[th] 2022. Prior to exercise of these warrants, the investors collectively held ~29% of Brain+ shares outstanding.

Lars Terney has exercised 188.548 warrants, via investment of DKK 308.842. This brings his combined shareholdings in Brain+, including beneficial ownership, to 1.055.402 shares.

Hanne Leth Hillman has exercised 69.425 warrants, via investment of DKK 113.718. This brings her combined shareholdings in Brain+, including beneficial ownership, to 87.000 shares.

Kim Baden-Kristensen has exercised 53.265 warrants, via investment of DKK 87.248. This brings his combined shareholdings in Brain+, including beneficial ownership, to 2.630.416 shares.

Contact Information

CEO, Kim Baden-Kristensen + 45 31393317, E-mail: kim@brain-plus.com,Brain+ A/S, Købmagergade 53, 3.

Certified Advisor: Keswick Global AG, + 43 1 740 408045 , E-mail: info@keswickglobal.com (%20info@keswickglobal.com)